Nanjing Leads Biolabs Co., Ltd. Class H 9887

NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (LBL-024), its proprietary PD-L1/4-1BB bispecific antibody, plus chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC), were presented in an oral presentation at the 2026 World Conference on Lung Cancer (WCLC). The updated data demonstrated robust and durable antitumor activity

Nanjing Leads Biolabs (SEHK:9887) reported that China's National Medical Products Administration accepted its NDA for Opamtistomig as a first in class PD-L1/4-1BB bispecific antibody for extrapulmonary neuroendocrine carcinoma. The company highlighted that, if approved, Opamtistomig could become the world's first approved antibody directly targeting 4-1BB. Nanjing Leads Biolabs also advanced Opamtistomig into key expansion phases in multiple clinical trials for esophageal squamous cell...

NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile. The s